CPT code 32561 describes the initial-day intrapleural administration of a fibrinolytic agent through a chest tube or catheter to dissolve fibrinous material in the pleural space. The code is clinically important for management of complicated pleural effusions and empyema when enzymatic breakdown of fibrinous loculations is indicated. Nationally, proper coding of this service affects clinical documentation, care coordination in inpatient and hospital outpatient settings, and claims adjudication for a procedure-intensive therapy.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and typical settings of service, followed by benchmarking and coverage considerations across major payers where available. The publication highlights coding elements tied to first-day treatment recognition and outlines the operational implications for hospital coding teams and billing staff. Data not available in the input is noted where applicable; the content focuses on clarifying what CPT code 32561 represents, why it matters to reimbursement and clinical workflows, and what elements clinicians and coders should expect to see documented for intrapleural fibrinolytic therapy.